Evidence mapPaperPMID 39350405Full record

ReviewCurrent drug targets2025

Advances in Cysteine Protease B Inhibitors for Leishmaniasis Treatment.

Ana Luisa Rodriguez Gini, Emilio Emilio João, Juliana Romano Lopes, Pamela Souza Tada Da Cunha, Angela Maria Arenas Velasquez, Marcia Aparecida Silva Graminha, Jean Leandro Dos Santos, Caue Benito Scarim

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ana Luisa Rodriguez GiniDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, SP, Brazil.
Emilio Emilio JoãoDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, SP, Brazil.
Juliana Romano LopesDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, SP, Brazil.
Pamela Souza Tada Da CunhaDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, SP, Brazil.
Angela Maria Arenas VelasquezDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil.
Marcia Aparecida Silva GraminhaDepartment of Clinical Analysis, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil.
Jean Leandro Dos SantosDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, SP, Brazil.
Caue Benito ScarimDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara, SP, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 302689/2020-6Financiadora de Estudos e Projetos (FINEP) 3348/2022Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2024/05739-6, 2023/05739-6
6 · The paper itself

Abstract

The expression and release of cysteine proteases by

Indexed as

Antiprotozoal AgentsCysteine Proteinase InhibitorsLeishmaniaLeishmaniasisProtozoan ProteinsAnimalsCysteine ProteasesDrug DesignDrug DiscoveryHumansAntiprotozoal AgentsCysteine ProteasesCysteine Proteinase InhibitorsProtozoan ProteinsCysteine protease Bdrug designdrug developmentleishmaniasisneglected tropical disease.new compounds

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.